Daily Cost of Ophthalmic Solutions for Treating Glaucoma in Japan

Ikeda, Hiroaki; Sato, Eiju; Kitaura, Teruaki; Fukuchi, Hiroshi; Kimura, Yasuhiro; Kihira, Kenji

doi:10.1016/s0021-5155(00)00299-9

Cited by 15 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Como apurado em nosso estudo, essa afirmativa somente é válida quando se especifica o procedimento de gotejamento adotado para a administração deste, sendo que diferentes metodologias produzem resultados que beneficiam determinados colírios. Ainda, existem trabalhos que analisaram custos de medicação antiglaucomatosa, porém adotaram diferentes métodos ou não descreveram em seus estudos a angulação em que o gotejo foi realizado, o que pode confundir a interpretação dos resultados (5,8,(11)(12)(13)(14)(15)(16) .…”

Section: Discussionunclassified

See 1 more Smart Citation

Considerações sobre o ângulo de administração de colírios antiglaucomatosos análogos das prostaglandinas

Estacia¹,

Tognon²

2008

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Section: Discussionunclassified

“…Vários trabalhos têm sido publicados sobre o custo do tratamento antiglaucomatoso com colírios, com base no núme-ro de gotas obtido de cada frasco (5,8,(11)(12)(13)(14)(15)(16) . É importante observar que a densidade das soluções oftalmológicas não tem papel significante na determinação do volume da gota (17) .…”

Section: Resumo Introduçãounclassified

Considerações sobre o ângulo de administração de colírios antiglaucomatosos análogos das prostaglandinas

Estacia¹,

Tognon²

2008

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…La evidencia clínica más reciente indica que los tratamientos combinados de estos fármacos pueden constituir una alternativa eficaz e igualmente segura. No obstante, pautas complejas que incluyan la administración de varios fármacos, pueden llevar a un peor cumplimiento del tratamiento del GPAA, lo que se considera una de las principales causas del fracaso del mismo (16 (17) observaron, al igual que otros estudios internacionales (18)(19)(20)(21)(22), que el grupo de beta-bloqueantes presentaba una eficacia hipotensora menor que los análogos de las prostaglandinas, pero dado su bajo precio, su ratio coste-eficacia hipotensora media (en euros por punto de porcentaje de reducción de PIO) era más bajo. La eficacia encontrada en nuestro estudio para los productos combinados está por encima de los valores hallados por Galindo et al para las monoterapias, mientras nuestras ratios de coste-eficacia media se sitúan entre los valores de Galindo et al para los beta-bloqueantes y análogos de prostaglandinas en monoterapia.…”

Section: Discussionunclassified

Análisis coste-eficacia de las combinaciones fijas de prostaglandinas/prostamida para el tratamiento del glaucoma

Martínez¹,

Slof²

2008

Arch Soc Esp Oftalmol

View full text Add to dashboard Cite

RESUMENObjetivo: Evaluar la relación coste-eficacia de las tres combinaciones fijas de prostaglandinas/prostamida con timolol actualmente disponibles en el mercado español [bimatoprost con timolol (BT) -Ganfort ® , latanoprost con timolol (LT) -Xalacom ® y travoprost con timolol (TT) -DuoTrav ® ]. Métodos: Dado que no existen estudios que comparen de una manera directa la eficacia de estos fár-macos, se llevó a cabo una revisión sistemática de la evidencia indirecta en lengua inglesa. Se estimaron el consumo de recursos sanitarios y su coste a partir de un modelo esquemático de la práctica clí-nica habitual en nuestro medio. Se calcularon para cada fármaco la relación coste-eficacia media y la relación coste-eficacia incremental, en términos de euros por punto porcentual de reducción de presión intraocular (PIO) en un periodo de tres meses. Resultados: BT redujo la PIO en un 35,1%, LT en un 35,0% y TT en un 34,7%. El coste-eficacia medio se estimó para BT en 5,34 por punto porcentual de reducción de PIO, para LT en 5,40 , y para TT en 5,45 . El coste-eficacia incremental (coste adicional por punto porcentual adicional de ARTÍCULO ORIGINAL ABSTRACT Objective: To assess the cost-efficacy of three fixed-combination glaucoma treatments currently available in Spain [bimatoprost with timolol (BT)-Ganfort ® , latanoprost with timolol (LT)-Xalacom ® , and travoprost with timolol (TT)-DuoTrav ® ]. Methods: Because no studies are available that give a direct comparison of these drugs, a systematic review was carried out to assess their efficacy. Resource consumption and costs were estimated using a model of usual local practice. For each of the three drugs, average and incremental cost-efficacy ratios were determined in terms of euros per percentage point of reduction of intraocular pressure (IOP) over a three-month period. Results: BT reduced IOP by 35.1%, LT by 35.0% and TT by 34.7%. Average cost-efficacy was estimated to be 5.34 per percentage point of IOP reduction with BT, 5.40 with LT, and 5.45 with TT. Incremental cost-efficacy (incremental cost per incremental percentage point of IOP reduction) was estimated to be 94.65 for LT vs. TT, and was negative for BT vs. TT and BT vs. LT, since in both cases BT was more efficacious and less expensive.

show abstract

“…FCs can reduce the flushing effect between different drugs, decrease the total usage frequency of drugs, and minimize the damage to the ocular surface caused by glaucoma medications and preservatives [9], and thus improve compliance. At present, several researchers from different countries have compared the daily costs of various antiglaucoma medications [10][11][12][13], but FCs were not included in most of the published papers. In this study, we aimed to compare the daily costs and cost effectiveness of the FCs currently available in China.…”

Section: Introductionmentioning

confidence: 99%

Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China

Guo

Huang

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Background. The aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in China. Methods. This study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA), travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.), bimatoprost 0.03% and timolol 0.5% (Ganfort; Allergan, Inc., Dublin, Ireland), and latanoprost 0.005% and timolol 0.5% (Xalacom; Pfizer, Inc., New York, NY, USA). Five bottles of each drug were measured. The mean actual volume, mean actual number of drops, volume per drop, daily cost, yearly cost, and per mmHg reduction cost for each drug were calculated. Results. The volumes per drop ranged from 32.61 ± 2.90 μl (DuoTrav) to 24.38 ± 0.23 μl (Ganfort). The number of usage days per bottle varied from 36 days (DuoTrav) to 61 days (Ganfort). Azarga had the lowest daily cost ($0.23) and yearly cost ($84.72), while DuoTrav had the highest daily cost ($0.79) and yearly cost ($287.02). Azarga costed $2.17–$3.30 per mmHg intraocular pressure reduction, which was lower than the other three drugs. For the prostaglandin and ß-adrenergic blocker FCs, Ganfort had the lowest daily cost ($0.35) and per mmHg reduction cost (from $3.40 to $4.04). Conclusions. The daily costs of these drugs were significantly different, with Azarga having the lowest daily cost and best cost effectiveness. For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical choice with its lower daily cost and per mmHg reduction cost. The results of this study could provide drug selection guidance from an economic perspective, but various factors should be considered when making a decision.

show abstract

Daily Cost of Ophthalmic Solutions for Treating Glaucoma in Japan

Cited by 15 publications

References 9 publications

Considerações sobre o ângulo de administração de colírios antiglaucomatosos análogos das prostaglandinas

Considerações sobre o ângulo de administração de colírios antiglaucomatosos análogos das prostaglandinas

Análisis coste-eficacia de las combinaciones fijas de prostaglandinas/prostamida para el tratamiento del glaucoma

Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China

Contact Info

Product

Resources

About